S. Louise Phanstiel - 25 Feb 2026 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Role
Director
Signature
By: Justin Hunter For: S. Louise Phanstiel
Issuer symbol
MYGN
Transactions as of
25 Feb 2026
Net transactions value
+$494,722
Form type
4
Filing time
27 Feb 2026, 16:46:18 UTC
Previous filing
17 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Phanstiel S. Louise Director 322 NORTH 2200 WEST, SALT LAKE CITY By: Justin Hunter For: S. Louise Phanstiel 27 Feb 2026 0001471518

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYGN Common Stock Purchase $28,890 +6,100 +3.4% $4.74 183,544 25 Feb 2026 Direct F1
transaction MYGN Common Stock Purchase $242,105 +50,407 +27% $4.80 233,951 26 Feb 2026 Direct F2
transaction MYGN Common Stock Purchase $223,728 +48,000 +21% $4.66 281,951 27 Feb 2026 Direct F3
holding MYGN Common Stock 33,119 25 Feb 2026 The Phanstiel Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.725 to $4.75, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.71 to $5.01, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.51 to $4.79, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.